12 Dec '24
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
No impact at this time on the listing of the Company’s Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn. , Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with
26 Nov '24
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
Exploration and evaluation of strategic alternatives continue WESTPORT, Conn. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and
13 Aug '24
Portage Biotech Announces 1-for-20 Reverse Stock Split
WESTPORT, Conn. , Aug. 13, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced that the Company’s Board of
26 Mar '24
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn. , March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination,
04 Jan '24
Portage Biotech Reports Business and Strategic Update
Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resources Company will evaluate range of strategic options WESTPORT, Conn. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel